Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intismeran autogene + pembrolizumab in high-risk melanoma
NCT05933577Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2023
- Primary completion
- Oct 2029
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 26
01
Overview
A Phase 3 trial of intismeran autogene in melanoma, sponsored by Merck & Co.. Started Jul 2023; status: active, not recruiting.
02
Drugs
intismeran autogene
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05933577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933577.